These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8227459)

  • 21. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 22. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated approval of drugs: ethics versus efficacy.
    Chary KV; Pandian K
    Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An introduction to analytical methods for the postmarketing surveillance of veterinary vaccines.
    Siev D
    Adv Vet Med; 1999; 41():749-74. PubMed ID: 9890058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 27. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
    Allan MC
    J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary by a child psychiatrist in industry on the assessment of drug safety.
    Allen AJ
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):288-91. PubMed ID: 17630860
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmarketing surveillance methodologies.
    Edlavitch SA
    Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmarketing surveillance for drug abuse.
    Arfken CL; Cicero TJ
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S97-105. PubMed ID: 12759200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
    Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
    BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 37. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. National adverse drug reaction reporting. 1984-1989.
    Faich GA
    Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US: insights into the construction of a sophisticated premarketing evaluation.
    Saito M; Iwasaki K
    J Artif Organs; 2017 Mar; 20(1):62-70. PubMed ID: 27709305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does $760 m a year of industry funding affect the FDA's drug approval process?
    Wolfe SM
    BMJ; 2014 Aug; 349():g5012. PubMed ID: 25096994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.